CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial
- DOI
- 10.1007/s10637-023-01410-2
- Published
- 2024-02
- Container
- Investigational New Drugs
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10637-023-01410-2,
title = {CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial},
author = {Andrew J. Armstrong and Ravit Geva and Hyun Cheol Chung and Charlotte Lemech and Wilson H. Miller and Aaron R. Hansen and Jong-Seok Lee and Frank Tsai and Benjamin J. Solomon and Tae Min Kim and Christian Rolfo and Vincent Giranda and Yixin Ren and Fang Liu and Bhargava Kandala and Tomoko Freshwater and Judy S. Wang},
year = {2024},
journal = {Investigational New Drugs},
doi = {10.1007/s10637-023-01410-2},
url = {https://doi.org/10.1007/s10637-023-01410-2}
}RIS
TY - JOUR TI - CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial AU - Andrew J. Armstrong AU - Ravit Geva AU - Hyun Cheol Chung AU - Charlotte Lemech AU - Wilson H. Miller AU - Aaron R. Hansen AU - Jong-Seok Lee AU - Frank Tsai AU - Benjamin J. Solomon AU - Tae Min Kim AU - Christian Rolfo AU - Vincent Giranda AU - Yixin Ren AU - Fang Liu AU - Bhargava Kandala AU - Tomoko Freshwater AU - Judy S. Wang PY - 2024 JO - Investigational New Drugs DO - 10.1007/s10637-023-01410-2 UR - https://doi.org/10.1007/s10637-023-01410-2 ER -
APA
Armstrong, A. J., Geva, R., Chung, H. C., Lemech, C., Miller, W. H., Hansen, A. R., Lee, J., Tsai, F., Solomon, B. J., Kim, T. M., Rolfo, C., Giranda, V., Ren, Y., Liu, F., Kandala, B., Freshwater, T., & Wang, J. S. (2024). CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial. Investigational New Drugs. https://doi.org/10.1007/s10637-023-01410-2
Source records
- crossref · retrieved 2026-09-27T07:02:57.863Z